ARTICLE | Clinical News
Praluent alirocumab regulatory update
July 18, 2016 7:00 AM UTC
The partners said Japan approved Praluent alirocumab to treat hypercholesterolemia and familial hypercholesterolemia ( FH) in patients at high cardiovascular risk with insufficient response to statin ...